Literature DB >> 9705381

Comparison of NucliSens and Amplicor monitor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Côte d'Ivoire.

J N Nkengasong1, M Kalou, C Maurice, C Bile, M Y Borget, S Koblavi, E Boateng, M Sassan-Morokro, E Anatole-Ehounou, P Ghys, A E Greenberg, S Z Wiktor.   

Abstract

We compared the sensitivity and accuracy of the NucliSens assay and those of both the standard and modified (addition of a new primer set, primer mix 1, supplied by Roche) Amplicor HIV Monitor assays to quantify human immunodeficiency virus type 1 (HIV-1) RNA in persons infected with HIV-1 subtype A in Abidjan, Côte d'Ivoire. Seventy-one plasma samples from HIV-1-seropositive persons at different stages of HIV infection and 15 samples from HIV antibody-negative persons were analyzed. The HIV-1 genetic subtype was determined either by DNA sequencing or by a restriction fragment length polymorphism assay. Of the 71 samples, 70 (98%) were subtype A and 1 was subtype G. Of the 70 subtype A samples, the proportion of RNA-positive plasma samples and mean HIV-1 RNA levels were significantly higher by the modified HIV Monitor assay (n = 67 [96%]; mean RNA levels, 5.2 log10 HIV-1 RNA copies/ml) than the NucliSens assay (n = 56 [80%]; 4.3 log10 HIV-1 RNA copies/ml) or the standard HIV Monitor assay (n = 44 [63%]; mean RNA levels, 3.8 log10 HIV-1 RNA copies/ml) (all P values were <0.05). The HIV-1 RNA levels by the modified HIV Monitor assay correlated significantly with those by the NucliSens assay (r = 0.76; P < 0.001) and the standard HIV Monitor assay (r = 0.57; P < 0.001), as did the RNA levels by the NucliSens and the standard HIV Monitor assays (r = 0.60; P < 0. 001). Lower CD4 cell counts were significantly correlated with higher HIV-1 RNA levels by all three assays (r = -0.47 for the NucliSens assay, -0.45 for the standard HIV Monitor assay, and -0.62 for the modified HIV Monitor assay). These results indicate that the modified HIV Monitor assay has the highest sensitivity and efficiency at quantifying the levels of RNA in persons infected with HIV-1 subtype A and thus constitutes a valuable tool for the monitoring of RNA levels in areas of Africa were HIV-1 subtype A is predominant.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705381      PMCID: PMC105151     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test.

Authors:  A M Vandamme; J C Schmit; S Van Dooren; K Van Laethem; E Gobbers; W Kok; P Goubau; M Witvrouw; W Peetermans; E De Clercq; J Desmyter
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-10-01

Review 2.  The puzzle of HIV-1 subtypes in Africa.

Authors:  W Janssens; A Buvé; J N Nkengasong
Journal:  AIDS       Date:  1997-05       Impact factor: 4.177

3.  Comparison of branched DNA and reverse transcriptase polymerase chain reaction for quantifying six different HIV-1 subtypes in plasma.

Authors:  A L Dunne; S M Crowe
Journal:  AIDS       Date:  1997-01       Impact factor: 4.177

4.  Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  H Revets; D Marissens; S de Wit; P Lacor; N Clumeck; S Lauwers; G Zissis
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 5.  Viral dynamics of HIV: implications for drug development and therapeutic strategies.

Authors:  D V Havlir; D D Richman
Journal:  Ann Intern Med       Date:  1996-06-01       Impact factor: 25.391

6.  Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G.

Authors:  D L Ellenberger; D Pieniazek; J Nkengasong; C C Luo; S Devare; C Maurice; M Janini; A Ramos; C Fridlund; D J Hu; I M Coulibaly; E Ekpini; S Z Wiktor; A E Greenberg; G Schochetman; M A Rayfield
Journal:  AIDS Res Hum Retroviruses       Date:  1999-01-01       Impact factor: 2.205

7.  Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma.

Authors:  R L Dewar; H C Highbarger; M D Sarmiento; J A Todd; M B Vasudevachari; R T Davey; J A Kovacs; N P Salzman; H C Lane; M S Urdea
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

8.  Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.

Authors:  C Pachl; J A Todd; D G Kern; P J Sheridan; S J Fong; M Stempien; B Hoo; D Besemer; T Yeghiazarian; B Irvine
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-04-15

9.  Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.

Authors:  Y Cao; D D Ho; J Todd; R Kokka; M Urdea; J D Lifson; M Piatak; S Chen; B H Hahn; M S Saag
Journal:  AIDS Res Hum Retroviruses       Date:  1995-03       Impact factor: 2.205

10.  Natural history of HIV-1 cell-free viremia.

Authors:  D R Henrard; J F Phillips; L R Muenz; W A Blattner; D Wiesner; M E Eyster; J J Goedert
Journal:  JAMA       Date:  1995-08-16       Impact factor: 56.272

View more
  10 in total

1.  Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.

Authors:  Jean-Christophe Plantier; Laurence Vergne; Florence Damond; Souleymane MBoup; Eitel MPoudi-NGole; Laurence Buzelay; Isabelle Farfara; Denys Brand; Martine Peeters; Françoise Brun-Vézinet; Eric Delaporte; Francis Barin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Comparison of LCx with other current viral load assays for detecting and quantifying human immunodeficiency virus type 1 RNA in patients infected with the circulating recombinant form A/G (CRF02).

Authors:  Alessandra Amendola; Licia Bordi; Claudio Angeletti; Enrico Girardi; Giuseppe Ippolito; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

3.  Performance of NucliSens HIV-1 EasyQ Version 2.0 compared with six commercially available quantitative nucleic acid assays for detection of HIV-1 in China.

Authors:  Sihong Xu; Aijing Song; Jianhui Nie; Xiuhua Li; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-10-01       Impact factor: 4.074

4.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target.

Authors:  M P de Baar; A M van der Schoot; J Goudsmit; F Jacobs; R Ehren; K H van der Horn; P Oudshoorn; F de Wolf; A de Ronde
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

6.  Quality of human immunodeficiency virus viral load testing in Australia.

Authors:  S J Best; A P Gust; E I Johnson; C H McGavin; E M Dax
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

7.  Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D G Murphy; L Côté; M Fauvel; P René; J Vincelette
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

8.  Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.

Authors:  Rute Antunes; Sofia Figueiredo; Inês Bártolo; Manuel Pinheiro; Lino Rosado; Isabel Soares; Helena Lourenço; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

Review 9.  Current practices in laboratory monitoring of HIV infection.

Authors:  Madhu Vajpayee; Teena Mohan
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

Review 10.  HIV-1 viral load assays for resource-limited settings.

Authors:  Susan A Fiscus; Ben Cheng; Suzanne M Crowe; Lisa Demeter; Cheryl Jennings; Veronica Miller; Richard Respess; Wendy Stevens
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.